SUNNYVALE, Calif., Oct. 10,
2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL)
("Ceribell"), a commercial-stage medical technology company focused
on transforming the diagnosis and management of patients with
serious neurological conditions, announced today the pricing of its
upsized initial public offering of 10,606,060 shares of its common
stock at a public offering price of $17.00 per share. In connection with the
offering, Ceribell has granted the underwriters a 30-day option to
purchase up to an additional 1,590,909 shares of common stock at
the initial public offering price, less underwriting discounts and
commissions. The shares are expected to begin trading on the Nasdaq
Global Select Market on October 11,
2024 under the ticker symbol "CBLL". The gross proceeds from
the offering, before deducting underwriting discounts and
commissions and other offering expenses payable by Ceribell, are
expected to be approximately $180.3
million, excluding any exercise of the underwriters' option
to purchase additional shares. The closing of the offering is
expected to occur on October 15,
2024, subject to satisfaction of customary closing
conditions.
BofA Securities and J.P. Morgan are acting as joint book-running
managers and as representatives of the underwriters for the
offering. William Blair, TD Cowen and Canaccord Genuity are acting
as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies
of the final prospectus relating to this offering, when available,
may be obtained from BofA Securities, Attention: Prospectus
Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; or J.P. Morgan, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at
prospectus-eq_fi@jpmchase.com and
postsalemanualrequests@broadridge.com.
A registration statement on Form S-1, including a prospectus,
relating to these securities was declared effective by the U.S.
Securities and Exchange Commission on October 10, 2024. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Ceribell
Ceribell is a commercial-stage medical
technology company focused on transforming the diagnosis and
management of patients with serious neurological conditions. The
Ceribell System is an AI-powered, rapidly
deployable point-of-care electroencephalography ("EEG")
platform designed to address the unmet needs of patients in the
acute care setting. The company is headquartered in Sunnyvale, Calif.
INVESTOR CONTACT
Brian Johnston or Laine Morgan
Gilmartin Group, LLC
investors@ceribell.com
MEDIA CONTACT
Corrie Rose
Press@ceribell.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ceribell-inc-announces-pricing-of-upsized-initial-public-offering-302273634.html
SOURCE Ceribell, Inc.